Novartis Ag (NVS) Operating Margin (2009 - 2026)
Novartis Ag's (NVS) quarterly Operating Margin came in at 32.97% in Q2 2026, down 164.0% year-over-year from 51.51% in Q2 2025, and up 2.08% quarter-over-quarter from 32.3% in Q1 2026.
Analysis
Novartis Ag (NVS) Operating Margin (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Operating Margin across 18 years of filings, most recently posting 32.97% for Q2 2026.
- In Q2 2026, Operating Margin fell 164.0% year-over-year to 32.97%; the TTM figure through Jun 2026 stood at 33.49% (up 691.0% YoY), while the FY2025 annual figure was 32.36%, up 345.0% from the prior year.
- Operating Margin came in at 32.97% for Q2 2026 at Novartis Ag, up from 32.3% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 44.75% in Q1 2023 to a low of 14.96% in Q3 2023.
- Average Operating Margin over 5 years is 28.28%, with a median of 30.18% recorded in 2024.
- Year-over-year, Operating Margin slumped 942 bps in 2022 and soared 2199 bps in 2023.
- Over 5 years, Operating Margin stood at 19.57% in 2022, then grew by 8 bps to 21.13% in 2023, then decreased by 6 bps to 19.88% in 2024, then surged by 76 bps to 34.91% in 2025, then declined by 6 bps to 32.97% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 32.97% in Q2 2026, 32.3% in Q1 2026, and 34.91% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.00 Bn | 621.25 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 446.05 Bn | 439.48 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 357.71 Bn | 350.56 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 268.09 Bn | 260.40 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 156.78 Bn | 145.08 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.12 Bn | 44.74 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 43.05 Bn | 43.05 Bn | - | - |
| 8 | Incyte | 24.84 Bn | 20.31 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.39 Bn | 18.73 Bn | 683.80 Mn | 42.23% |
| 10 | Neurocrine Biosciences | 15.92 Bn | 15.53 Bn | 935.80 Mn | 15.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.97% |
| Mar 31, 2026 | 32.30% |
| Dec 31, 2025 | 34.91% |
| Sep 30, 2025 | 32.36% |
| Jun 30, 2025 | 34.61% |
| Mar 31, 2025 | 35.24% |
| Dec 31, 2024 | 19.88% |
| Sep 30, 2024 | 28.29% |
| Jun 30, 2024 | 32.08% |
| Mar 31, 2024 | 43.83% |
| Dec 31, 2023 | 21.13% |
| Sep 30, 2023 | 14.96% |
| Jun 30, 2023 | 24.54% |
| Mar 31, 2023 | 44.75% |
| Dec 31, 2022 | 19.57% |
| Sep 30, 2022 | 17.40% |
| Jun 30, 2022 | 17.43% |
| Mar 31, 2022 | 22.76% |
| Dec 31, 2021 | 23.23% |
| Sep 30, 2021 | 24.81% |